Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
IMMUNOVANT INC (IMVT) Stock Price & Overview
NASDAQ:IMVT • US45258J1025
Current stock price
27.5 USD
+0.55 (+2.04%)
Last:
The current stock price of IMVT is 27.5 USD. Today IMVT is up by 2.04%. In the past month the price increased by 8.49%. In the past year, price increased by 70.57%.
IMVT Key Statistics
52-Week Range13.36 - 30.09
Current IMVT stock price positioned within its 52-week range.
1-Month Range23.24 - 30.09
Current IMVT stock price positioned within its 1-month range.
- Market Cap
- 5.597B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.69
- Dividend Yield
- N/A
IMVT Stock Performance
Today
+2.04%
1 Week
-8.61%
1 Month
+8.49%
3 Months
+3.65%
Longer-term
6 Months +9.20%
1 Year +70.57%
2 Years -1.79%
3 Years +66.98%
5 Years +71.88%
10 Years N/A
IMVT Stock Chart
IMVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMVT. When comparing the yearly performance of all stocks, IMVT is one of the better performing stocks in the market, outperforming 87.34% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
IMVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMVT. No worries on liquidiy or solvency for IMVT as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IMVT Earnings
Next Earnings DateMay 27, 2026
Last Earnings DateFeb 6, 2026
PeriodQ3 / 2026
EPS Reported-$0.61
Revenue Reported
EPS Surprise 16.27%
Revenue Surprise %
IMVT Forecast & Estimates
24 analysts have analysed IMVT and the average price target is 41.14 USD. This implies a price increase of 49.6% is expected in the next year compared to the current price of 27.5.
Analysts
Analysts82.5
Price Target41.14 (49.6%)
EPS Next Y2.35%
Revenue Next YearN/A
IMVT Index Membership
IMVT is currently included in the following stock indexes tracked on ChartMill.
IMVT Financial Highlights
Over the last trailing twelve months IMVT reported a non-GAAP Earnings per Share(EPS) of -2.69. The EPS decreased by -2.67% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-464.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.11% | ||
| ROE | -47.07% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%19.74%
Sales Q2Q%N/A
EPS 1Y (TTM)-2.67%
Revenue 1Y (TTM)N/A
IMVT Ownership
Ownership
Inst Owners53.3%
Shares203.53M
Float84.40M
Ins Owners1.28%
Short Float %23.11%
Short Ratio14.55
IMVT Industry Overview
IMVT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.6
- Average Fwd P/E
- 22.2
- Average Debt/Equity
- 2.2
IMVT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.94 | 360.632B | ||
| AMGN | AMGEN INC | 15.29 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.93 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.11 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.33 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.72 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 25.03B | ||
| INCY | INCYTE CORP | 10.82 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMVT
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Company Info
IPO: 2019-05-14
IMMUNOVANT INC
320 West 37Th Street
New York City NEW YORK 10018 US
CEO: Peter Salzmann
Employees: 362
Phone: 13026365400
IMMUNOVANT INC / IMVT FAQ
Can you describe the business of IMMUNOVANT INC?
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
What is the stock price of IMMUNOVANT INC today?
The current stock price of IMVT is 27.5 USD. The price increased by 2.04% in the last trading session.
Does IMMUNOVANT INC pay dividends?
IMVT does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMVT stock?
IMVT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists IMVT stock?
IMVT stock is listed on the Nasdaq exchange.
What do analysts say about IMMUNOVANT INC (IMVT) stock?
24 analysts have analysed IMVT and the average price target is 41.14 USD. This implies a price increase of 49.6% is expected in the next year compared to the current price of 27.5.
Would investing in IMMUNOVANT INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMVT.